Accelerated sales growth of 22% in Q4 2024, taking annual sales to €29.1 million, +9% vs. 2023 Order intake of €7.8 million in Q4 2024 Backlog1 to €21.9 million as of December 31, 2024 ...

NanoViricides, Inc. (NYSE American:NNVC) (the “Company”) today announced that it has engaged a Clinical Research Organization (CRO) to conduct a Phase II clinical trial advancing its broad-spectrum ...